146 related articles for article (PubMed ID: 38367684)
1. Toxicology, pharmacokinetics, and immunogenicity studies of CCR4-IL2 bispecific immunotoxin in rats and minipigs.
Wang Z; Ramakrishna R; Wang Y; Qiu Y; Ma J; Mintzlaff D; Zhang H; Li B; Hammell B; Lucia MS; Pomfret E; Su AA; Washington KM; Mathes DW; Wang Z
Eur J Pharmacol; 2024 Apr; 968():176408. PubMed ID: 38367684
[TBL] [Abstract][Full Text] [Related]
2. CCR4-IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T-cell lymphoma in a mouse CTCL model.
Wang Z; Ma J; Zhang H; Ramakrishna R; Mintzlaff D; Mathes DW; Pomfret EA; Lucia MS; Gao D; Haverkos BM; Wang Z
FEBS Open Bio; 2023 Jul; 13(7):1309-1319. PubMed ID: 37157185
[TBL] [Abstract][Full Text] [Related]
3. Bispecific human IL2-CCR4 immunotoxin targets human cutaneous T-cell lymphoma.
Wang H; Wang Z; Zhang H; Qi Z; Johnson AC; Mathes D; Pomfret EA; Rubin E; Huang CA; Wang Z
Mol Oncol; 2020 May; 14(5):991-1000. PubMed ID: 32107846
[TBL] [Abstract][Full Text] [Related]
4. Diphtheria-toxin based anti-human CCR4 immunotoxin for targeting human CCR4(+) cells in vivo.
Wang Z; Wei M; Zhang H; Chen H; Germana S; Huang CA; Madsen JC; Sachs DH; Wang Z
Mol Oncol; 2015 Aug; 9(7):1458-70. PubMed ID: 25958791
[TBL] [Abstract][Full Text] [Related]
5. Dosing optimization of CCR4 immunotoxin for improved depletion of CCR4
Wang Z; Louras NJ; Lellouch AG; Pratts SG; Zhang H; Wang H; Huang CA; Cetrulo CL; Madsen JC; Sachs DH; Wang Z
Mol Oncol; 2018 Aug; 12(8):1374-1382. PubMed ID: 29873181
[TBL] [Abstract][Full Text] [Related]
6. Porcine Treg depletion with a novel diphtheria toxin-based anti-human CCR4 immunotoxin.
Wang Z; Navarro-Alvarez N; Shah JA; Zhang H; Huang Q; Zheng Q; Madsen JC; Sachs DH; Huang CA; Wang Z
Vet Immunol Immunopathol; 2016 Dec; 182():150-158. PubMed ID: 27863545
[TBL] [Abstract][Full Text] [Related]
7. Treg depletion in non-human primates using a novel diphtheria toxin-based anti-human CCR4 immunotoxin.
Wang Z; Pratts SG; Zhang H; Spencer PJ; Yu R; Tonsho M; Shah JA; Tanabe T; Powell HR; Huang CA; Madsen JC; Sachs DH; Wang Z
Mol Oncol; 2016 Apr; 10(4):553-65. PubMed ID: 26643572
[TBL] [Abstract][Full Text] [Related]
8. Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells.
Chang DK; Sui J; Geng S; Muvaffak A; Bai M; Fuhlbrigge RC; Lo A; Yammanuru A; Hubbard L; Sheehan J; Campbell JJ; Zhu Q; Kupper TS; Marasco WA
Mol Cancer Ther; 2012 Nov; 11(11):2451-61. PubMed ID: 22869555
[TBL] [Abstract][Full Text] [Related]
9. Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma.
Lansigan F; Stearns DM; Foss F
Cancer Manag Res; 2010 Feb; 2():53-9. PubMed ID: 21188096
[TBL] [Abstract][Full Text] [Related]
10. Human anti-CCR4 minibody gene transfer for the treatment of cutaneous T-cell lymphoma.
Han T; Abdel-Motal UM; Chang DK; Sui J; Muvaffak A; Campbell J; Zhu Q; Kupper TS; Marasco WA
PLoS One; 2012; 7(9):e44455. PubMed ID: 22973452
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
Yamamoto K; Utsunomiya A; Tobinai K; Tsukasaki K; Uike N; Uozumi K; Yamaguchi K; Yamada Y; Hanada S; Tamura K; Nakamura S; Inagaki H; Ohshima K; Kiyoi H; Ishida T; Matsushima K; Akinaga S; Ogura M; Tomonaga M; Ueda R
J Clin Oncol; 2010 Mar; 28(9):1591-8. PubMed ID: 20177026
[TBL] [Abstract][Full Text] [Related]
12. CCR4 in cutaneous T-cell lymphoma: Therapeutic targeting of a pathogenic driver.
Nicolay JP; Albrecht JD; Alberti-Violetti S; Berti E
Eur J Immunol; 2021 Jul; 51(7):1660-1671. PubMed ID: 33811642
[TBL] [Abstract][Full Text] [Related]
13. A Narrative Review of the State of the Art of CCR4-Based Therapies in Cutaneous T-Cell Lymphomas: Focus on Mogamulizumab and Future Treatments.
Zengarini C; Guglielmo A; Mussi M; Motta G; Agostinelli C; Sabattini E; Piraccini BM; Pileri A
Antibodies (Basel); 2024 Apr; 13(2):. PubMed ID: 38804300
[TBL] [Abstract][Full Text] [Related]
14. Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma.
Beygi S; Duran GE; Fernandez-Pol S; Rook AH; Kim YH; Khodadoust MS
Blood; 2022 Jun; 139(26):3732-3736. PubMed ID: 35436328
[TBL] [Abstract][Full Text] [Related]
15. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model.
Ito A; Ishida T; Yano H; Inagaki A; Suzuki S; Sato F; Takino H; Mori F; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
Cancer Immunol Immunother; 2009 Aug; 58(8):1195-206. PubMed ID: 19048251
[TBL] [Abstract][Full Text] [Related]
16. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome.
Ni X; Jorgensen JL; Goswami M; Challagundla P; Decker WK; Kim YH; Duvic MA
Clin Cancer Res; 2015 Jan; 21(2):274-85. PubMed ID: 25376389
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetic Modeling of Mogamulizumab in Adults With Cutaneous T-Cell Lymphoma or Adult T-Cell Lymphoma.
Mukai M; Maeda H; Narushima K; Mould DR; Greene D
J Clin Pharmacol; 2020 Jan; 60(1):58-66. PubMed ID: 31840838
[TBL] [Abstract][Full Text] [Related]
18. Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas.
Remer M; Al-Shamkhani A; Glennie M; Johnson P
Immunotherapy; 2014; 6(11):1187-206. PubMed ID: 25496334
[TBL] [Abstract][Full Text] [Related]
19. Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma.
Watanabe K; Gomez AM; Kuramitsu S; Siurala M; Da T; Agarwal S; Song D; Scholler J; Rotolo A; Posey AD; Rook AH; Haun PL; Ruella M; Young RM; June CH
Blood Adv; 2023 Jul; 7(14):3416-3430. PubMed ID: 37058474
[TBL] [Abstract][Full Text] [Related]
20. Serum CCL22 levels decreased in parallel with disease activity in CCR4-positive mycosis fungoides treated with mogamulizumab.
Ohuchi K; Fujimura T; Lyu C; Amagai R; Muto Y; Aiba S
Dermatol Ther; 2020 Nov; 33(6):e14099. PubMed ID: 32725764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
